Literature DB >> 19687580

Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis.

Ismail Sari1, Levent Kebapcilar, Ahmet Alacacioglu, Oktay Bilgir, Yasar Yildiz, Ali Taylan, Arif Yuksel, Didem L Kozaci.   

Abstract

OBJECTIVE: Endothelial dysfunction is present in ankylosing spondylitis (AS). However, the etiology of events is still unclear. The aim of the present study was to investigate whether there are abnormalities in nitric oxide (NO) metabolism and endothelin-1 (ET-1) in AS patients.
METHODS: Subjects without any classical cardiovascular (CV) risk factors were studied. Fasting glucose, serum lipids, high sensitive CRP (hsCRP), ESR, asymmetric dimethylarginine (ADMA) and ET-1 were studied. Patients were also evaluated with the Bath Ankylosing Spondylitis Metrology Index, Bath Ankylosing Spondylitis Functional Index, and the Bath Ankylosing Spondylitis Disease Activity Index.
RESULTS: A total of 48 AS patients (38.6+/-10.6 years; 36M/12F) and 38 controls (36.4+/-11.1 years; 27M/11F) were studied. Acute phase reactants including hsCRP, and ESR were significantly increased in the patients group (p<0.05). Serum ADMA concentrations were also significantly higher in AS than in controls. Plasma levels of ET-1 did not differ between the groups (p>0.05). Comparison of three groups (conventional and anti-TNF treatment groups and controls) revealed that ADMA was significantly higher in the conventional treated AS than in controls. The levels of ADMA were not different between anti-TNF group and healthy subjects. Plasma ET-1 concentrations were similar between groups (p>0.05). Correlation analysis yielded significant correlations between ADMA, hsCRP, LDL cholesterol, HDL cholesterol and triglycerides (p<0.05).
CONCLUSION: The increased ADMA levels obtained in a group of relatively young AS patients who did not have classical CV risk factors suggest that NO metabolism is impaired in AS. On the other hand, anti-TNF treatments may have a beneficial effect on vascular function in AS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687580     DOI: 10.2169/internalmedicine.48.2193

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  14 in total

1.  Relationship between asymmetric dimethylarginine and endothelial dysfunction in patients with rheumatoid arthritis.

Authors:  Taşkın Şentürk; Nergiz Yılmaz; Gökhan Sargın; Kutsi Köseoğlu; Çiğdem Yenisey
Journal:  Eur J Rheumatol       Date:  2016-09-01

2.  Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade.

Authors:  Ashit Syngle; Kanchan Vohra; Anjali Sharma; L Kaur
Journal:  Clin Rheumatol       Date:  2010-03-05       Impact factor: 2.980

3.  Evaluation of various endothelial biomarkers in ankylosing spondylitis.

Authors:  Ali Taylan; Ismail Sari; Didem L Kozaci; Yasar Yildiz; Safak Bilge; Isil Coker; Sergir Maltas; Necati Gunay; Nurullah Akkoc
Journal:  Clin Rheumatol       Date:  2011-05-10       Impact factor: 2.980

4.  Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study.

Authors:  Gian Luca Erre; Pietro Sanna; Angelo Zinellu; Alessandra Ponchietti; Patrizia Fenu; Salvatore Sotgia; Ciriaco Carru; Antonello Ganau; Giuseppe Passiu
Journal:  Clin Rheumatol       Date:  2010-10-14       Impact factor: 2.980

5.  Evaluation of circulating endothelial biomarkers in familial Mediterranean fever.

Authors:  Baris Onder Pamuk; Ismail Sari; Sema Selcuk; Goksel Gokce; Didem Leyla Kozaci
Journal:  Rheumatol Int       Date:  2013-01-29       Impact factor: 2.631

6.  SMAD-specific E3 ubiquitin ligase 2 promotes angiogenesis by facilitating PTX3 degradation in MSCs from patients with ankylosing spondylitis.

Authors:  Mengjun Ma; Wen Yang; Zhaopeng Cai; Peng Wang; Hongyu Li; Rujia Mi; Yuhang Jiang; Zhongyu Xie; Pengfei Sui; Yanfeng Wu; Huiyong Shen
Journal:  Stem Cells       Date:  2021-02-06       Impact factor: 6.277

Review 7.  Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis.

Authors:  Fernanda Genre; Raquel López-Mejías; José A Miranda-Filloy; Begoña Ubilla; Beatriz Carnero-López; Ricardo Blanco; Trinitario Pina; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Biomed Res Int       Date:  2014-03-18       Impact factor: 3.411

Review 8.  Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.

Authors:  Theodoros Dimitroulas; Aamer Sandoo; George D Kitas
Journal:  Int J Mol Sci       Date:  2012-09-26       Impact factor: 5.923

9.  Is there a relationship between endothelial nitric oxide synthase gene polymorphisms and ankylosing spondylitis?

Authors:  Ismail Sari; Yusuf Ziya Igci; Gercek Can; Ali Taylan; Dilek Solmaz; Bulent Gogebakan; Servet Akar; Zeynep Eslik; Giray Bozkaya; Nurullah Akkoc
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

10.  Determination of serum methylarginine levels by tandem mass spectrometric method in patients with ankylosing spondylitis.

Authors:  Duygu Eryavuz Onmaz; Kevser Isik; Abdullah Sivrikaya; Sedat Abusoglu; İlknur Albayrak Gezer; Gulsum Abusoglu; Fatma Humeyra Yerlikaya; Ali Unlu
Journal:  Amino Acids       Date:  2021-07-17       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.